Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Access Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Access Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Access Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Access Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Access Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Access Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Access Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Access Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Access Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Access Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Access Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Access Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Access Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Access Pharmaceuticals, Inc. Snapshot 5 Access Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Access Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Access Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Access Pharmaceuticals, Inc. - Pipeline Products Glance 11 Access Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Access Pharmaceuticals, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Access Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 13 Unknown Products/Combination Treatment Modalities 13 Access Pharmaceuticals, Inc. - Drug Profiles 14 AP-5346 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 CobaCyte Targeted Therapeutics For Oncology 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CobOral hGH 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CobOral Insulin 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 GLP-1 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Oral Fertility Drugs 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Prolindaun 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 RNAi Therapeutics 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Access Pharmaceuticals, Inc. - Pipeline Analysis 23 Access Pharmaceuticals, Inc. - Pipeline Products by Target 23 Access Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 24 Access Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 25 Access Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 26 Access Pharmaceuticals, Inc. - Recent Pipeline Updates 27 Access Pharmaceuticals, Inc. - Dormant Projects 28 Access Pharmaceuticals, Inc. - Discontinued Pipeline Products 29 Discontinued Pipeline Product Profiles 29 Thiarabine 29 Access Pharmaceuticals, Inc. - Company Statement 30 Access Pharmaceuticals, Inc. - Locations And Subsidiaries 32 Head Office 32 Other Locations & Subsidiaries 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 34 Disclaimer 34
List of Tables Access Pharmaceuticals, Inc., Key Information 5 Access Pharmaceuticals, Inc., Key Facts 5 Access Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Access Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Access Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Access Pharmaceuticals, Inc. - Phase II, 2014 11 Access Pharmaceuticals, Inc. - Preclinical, 2014 12 Access Pharmaceuticals, Inc. - Unknown, 2014 13 Access Pharmaceuticals, Inc. - Pipeline by Target, 2014 23 Access Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 24 Access Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 25 Access Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 26 Access Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 27 Access Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 28 Access Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 29 Access Pharmaceuticals, Inc., Subsidiaries 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.